Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients

• Main Authors: Thomas Monfeuga (Author), Jenny Norlin (Author), Anne Bugge (Author), Elisabeth D. Gaalsgaard (Author), Cesar A. Prada-Medina (Author), Markus Latta (Author), Sanne S. Veidal (Author), Pia S. Petersen (Author), Michael Feigh (Author), Dorte Holst (Author)
• Format: Book
• Published: Elsevier, 2024-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: The metabolic benefits of GLP-1 receptor (GLP-1R) agonists on glycemic and weight control are well established as therapy for type 2 diabetes and obesity. Glucagon's ability to increase energy expenditure is well described, and the combination of these mechanisms-of-actions has the p...